• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Twin Pregnancy Outcomes Following Confirmation of Viability in the First Trimester

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Litwinska et al. (Ultrasound in Obstetrics & Gynecology, 2019) compared pregnancy outcomes in twin pregnancies with two live fetuses at 11 to 13 weeks
  • Laser surgery for severe TTTS and sFGR was also incorporated to assess the outcome of MCDA twins

METHODS:

  • Retrospective analysis of prospectively collected data (between 2002 and 2019)
  • Participants
    • Twin pregnancies undergoing routine ultrasound examination at 11 to 13 weeks
    • No anomalies
  • Study design
    • Compared dichorionic (DC), monochorionic diamniotic (MCDA) and monochorionic monoamniotic (MCMA) for the following outcomes
      • Overall survival | Fetal loss at < 24 weeks’ gestation | Perinatal death at ≥ 24 weeks | Delivery at < 37 and < 32 weeks | Birth weight < 5th percentile

RESULTS:

  • A total of 6,225 twin pregnancies were examined
    • DC: 78.7%
    • MCDA: 20.5%
    • MCMA: 0.9%
  • Loss at < 24 weeks’ gestation
    • DC twins: 2.3%
    • MCDA twins: 7.7%
      • Relative risk (RR) 3.258 (95% CI, 2.706 to 3.923)
    • MCMA twins: 21.8%
      • RR 9.289 (95% CI, 6.377 to 13.530)
  • Perinatal death at ≥ 24 weeks in all twins that were alive at 24 weeks
    • DC twins: 1.0%
    • MCDA twins: 2.5%
      • RR 2.456 (95% CI, 1.779 to 3.389)
    • MCMA twins: 9.3%
      • RR 9.130 (95% CI, 4.584 to 18.184)
  • Preterm birth at < 37 weeks’ gestation in pregnancies with at least one liveborn twin
    • DC twins: 48.6%
    • MCDA twins: 88.5%
      • RR 1.824 (95% CI, 1.760 to 1.890)
    • MCMA twins: 100%
      • RR 2.060 (95% CI, 2.000 to 2.121)
  • Preterm birth at < 32 weeks
    • DC twins: 7.4%
    • MCDA twins: 14.2%
      • RR 1.920 (95% CI, 1.616 to 2.281)
    • MCMA twins: 26.8%
      • RR 3.637 (95% CI, 2.172 to 6.089)
  • SGA (with at least one liveborn twin)
    • DC twins: 31.2%
    • MCDA twins: 37.8%
      • RR 1.209 (95% CI, 1.138 to 1.284)
    • MCMA twins: (33.3%)
      • Not statistically different from DC
  • 10% of MCDA twins had endoscopic laser ablation for twin–twin transfusion syndrome (TTTS) and/or selective fetal growth restriction (sFGR)
    • Both fetuses survived: 55.9% of cases
    • One fetus survived: 22.5%
    • No survivors: 21.6%  
    • Total fetal loss rate at < 24 weeks’ gestation for MCDA twins would have been 13.5% if laser intervention had not been performed  

CONCLUSION:

  • Compared to DC twins, fetal loss, perinatal death, and preterm birth are elevated for MCDA and especially MCMA twins
  • Fetal loss rate for MCDA twins mitigated by the use of laser surgery been used for all cases of early TTTS and/or sFGR
  • The authors suggest how the data from this study be used

These data would be useful in counseling parents as to the likely outcome of their pregnancy and in defining strategies for surveillance and interventions in the management of the different types of twin pregnancy 

Learn More – Primary Sources:

Outcome of twin pregnancy with two live fetuses at 11–13 weeks’ gestation

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Laser Surgery for Twin-to-Twin-Transfusion-Syndrome and Behavioral Outcomes at 2 Years
The MONOMONO Study: Inpatient or Outpatient Surveillance for Monochorionic/Monoamniotic Twins?
Can Obstetric History Predict Preterm Birth Risk in Twins?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site